BioNTech SE BNTX
NASDAQ BNTX
$103.76 +0.88 (+0.86%)
As of: Sep 4, 2026 · 3:59 PM EDT

BioNTech SE (BNTX) Net Income Growth (3y) (2021 - 2026)

Analysis

BioNTech SE (BNTX) Net Income Growth (3y) (2021 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 6.30%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 10.23%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 116.82%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 17.25%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 37.89%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 37.44%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -38.56%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 62.15%
10 BioNTech SE 25.06 Bn 11.41 Bn 10.00 Mn -11.39%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -11.39%
Mar 31, 2026 -38.13%
Dec 31, 2025 -27.76%
Sep 30, 2025 -26.22%
Jun 30, 2025 -28.83%
Mar 31, 2025 -27.27%
Dec 31, 2024 -66.17%
Sep 30, 2024 -68.88%
Jun 30, 2024 -28.81%
Mar 31, 2024 -28.70%
Dec 31, 2023 110.50%
Sep 30, 2023 -10.68%
Jun 30, 2023 -108.77%
Mar 31, 2023 155.26%
Dec 31, 2022 300.78%
Sep 30, 2022 353.73%
Jun 30, 2022 283.15%
Mar 31, 2022 435.45%
Dec 31, 2021 1,521.14%
Sep 30, 2021 541.87%